Silymarin improved OS, renal fibrosis, podocyte injury, and inflammation in experimental diabetic rats via inhibition of TGF‐β/Smad and JAK2/STAT3/suppressor of cytokine signaling 1 pathways (Liu, Wang, Zhang, et al. 2023). The gene discussed is JAK2; the disease is renal fibrosis.